Hiromasa Morikawa

Publications

• Mini Review   
  Overview of factors associated with the effectiveness of tegafur-uracil treatment
  Author(s): Reo Hamaguchi*, Ryoko Narui, Hiromasa Morikawa and Hiromi Wada
  
  Pyrimidine fluoride anticancer drugs are used for the treatment of various cancers, such as lung cancer, colorectal cancer, gastric cancer, and breast cancer. In particular, tegafur-uracil treatment is well established as a postoperative adjuvant chemotherapy for Non-Small Cell Lung Cancer (NSCLC) patients, although the effectiveness of treatment differs depending on the type of cancer cells and the state of progression. Some characteristics of cancer cells may be associated with their treatment responses to tegafur-uracil. First, the genomic profiles of cancer cells may affect their response to tegafur-uracil therapy, although it remains unclear as to what specific genomic profiles of NSCLCs are associated with favorable treatment outcomes. Second, the tumor microenvironment that is created by the unique metabolic characteristics of cancer cells and is known to be associated with can.. View More»
  

  Abstract PDF